Acs Fall 2024 Vvd-130037 Vvd1300374. Current such mutations include the following: Vividion has already disclosed work on covalent keap1 inhibitors, but at the recent acs fall 2024 meeting, the structure and discovery story of their clinical oral covalent activator of.

Choose from thousands of presentations, network, attend courses and visit the expo. Current such mutations include the following: